Last year, animal rights group PETA urged securities regulators to investigate Charles River Laboratories for allegedly misleading investors about its sales and purchases of long-tailed macaques, widely used in pharmaceutical research. The company faced accusations of importing thousands of non-human primates illegally and sourcing some from firms linked to an international smuggling ring, as well as falsely labeling monkeys sold to clients. Charles River Laboratories International Inc. CRL stock is trading ...

Key Takeaways Charles River Laboratories International, Inc. (CRL) reported second-quarter 2025 adjusted earnings per share (EPS) of $3.12, which rose 11.4% year over year. The figure surpassed the Zacks Consensus Estimate by 24.8%. On a GAAP basis, the company reported earnings of $1.06 per share compared with the year-ago quarter's level of $1.74. CRL's Q2 Revenues Revenues totaled $1.03 billion, which beat the Zacks Consensus Estimate by 5%. The top line rose 0.6% from the year-ago quarter's level (down ...